Results 271 to 280 of about 829,320 (360)

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

Neoadjuvant treatment and premastectomy radiotherapy: oncological and surgical outcomes. [PDF]

Gland Surg
Bannier M, Cohen M, Tallet A, de Nonneville A, Houvenaeghel G.   +4 more
europepmc   +1 more source

The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up. [PDF]

BMC Cancer
Egelberg M, De Marchi T, Schultz N, Tran L, Karlsson P, Holmberg E, Pekar G, Killander F, Niméus E.   +8 more
europepmc   +1 more source

Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer [PDF]

, 2019
al, et, Mutch, David, Powell, Matthew A.
core   +1 more source

Enhancing antitumor immunity through the combination of cholesterolized TLR7 agonist liposomes and radiotherapy: a role for IL‐1β and the inflammasome pathway

Cancer Communications, EarlyView.
Abstract Background Radiotherapy (RT) is a key treatment modality in cancer therapy, utilizing high‐energy radiation to directly kill tumor cells. Recent research has increasingly highlighted RT's potential to indirectly enhance antitumor immunity. However, this immune activation alone often fails to generate sustained systemic antitumor responses.
Xuejiao Han, Yuan Cheng, Dandan Wan, Aqu Alu, Ziqi Zhang, Zhenfei Bi, Manni Wang, Yan Tang, Weiqi Hong, Siyuan Chen, Li Chen, Yuquan Wei   +11 more
wiley   +1 more source

Oncologic outcomes following neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma. [PDF]

Front Immunol
Li G, Wang J, Fang Q, Dai L, Du W.
europepmc   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

Cancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong, Xintong Xie, Juan Wu, Xiangyu Wang, Wenxiang Zhang, Shuowen Wang, Daria Valerievna Abbasova, Yi Fang, Hongnan Jiang, Jidong Gao, Jing Wang   +10 more
wiley   +1 more source

Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand. [PDF]

Curr Oncol
Maddula M, McNamee N, Gan HK, Satgunaseelan L, Koh ES, Han CH, Thavaneswaran S.   +6 more
europepmc   +1 more source

Clinicopathological features and patterns of treatment of patients with endometrial cancer in Brazil. [PDF]

J Gynecol Oncol
Arenhardt MP, Giannecchini GV, Santos Thuler LC, de Melo AC.   +3 more
europepmc   +1 more source

Leveraging real-world data for continuous evaluation of computational clinical practice guidelines. [PDF]

BMJ Health Care Inform
Ebben KCWJ, de Kroon CD, Schmeink CE, van der Hel OL, van Vegchel T, Thissen M, de Hingh IHJT, van der Werf J.   +7 more
europepmc   +1 more source